This observation is of clinical importance and would be in favor of novel treatment concepts combining JQ1 or similar BRD4 inhibitors and ARA-C in patients with relapsing or refractory AML in clinical trials. This evidence concerns the gene BRD4 and acute myeloid leukemia.